Journal of the Japan Diabetes Society
Online ISSN : 1881-588X
Print ISSN : 0021-437X
ISSN-L : 0021-437X
Search
Advanced search
OR
Browse
Search
Volume 51, Issue 9
Displaying 1-13 of 13 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Metabolic Modulators and Primary Prevention of Type 2 Diabetes—on the Basis of Result of Basic and Clinical Study
Original Article
  • Risk of Blood Glucose Measurements with Handheld Meters in Anemia Patient
    Fumiatsu Yakushiji, Hiroshi Fujita, Mutsuko Yasuda, Ken Taniguchi, Kaz ...
    2008 Volume 51 Issue 9 Pages 837-843
    Published: 2008
    Released on J-STAGE: May 20, 2009
    DOIhttps://doi.org/10.11213/tonyobyo.51.837
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Backgrounds: Hand-held blood sugar meter operation is reported to have become abnormal at experimentally artificial hematocrit. We experimentally and clinically evaluated measurement with especially low hematocrit.
    Methods: We first prepared three affiliated samples-artificial Ht adjusted blood (1), whole blood from anemic patients (2), and serial samples of blood from an anemic patient with diabetes (3)-and calculated hand-held blood sugar meters for their bias.
    Results: We found clinically that sugar concentration discrepancies using hand-held meters are significant in anemic patients.
    Conclusion: Although convenient to use, hand-held blood sugar meters present risks in measurement, especially in anemic patients. The approved Ht blood sampling ranges of these meters must thus be taken into account in their use.
    View full abstract
    Download PDF (511K)
Case Report
  • A Case of Type 2 Diabetes Mellitus Complicated with Gait Disorders Due to Thiamine Deficiency
    T. Murata, K. Ito, Y. Takagi, E. Mori, M. Ando, R. Nakagawachi, M. Abe ...
    2008 Volume 51 Issue 9 Pages 845-848
    Published: 2008
    Released on J-STAGE: May 20, 2009
    DOIhttps://doi.org/10.11213/tonyobyo.51.845
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    [in Japanese]
    View full abstract
    Download PDF (320K)
  • A Case of Congenital Partial Lipodystrophy without Lamin A/C and PPARγ Mutations (Köbberling Type or Variety): A Long-term Follow-up Regarding the Efficacy of Thiazolidinediones (pioglitazone)
    Haruka Sasaki, Kumiko Ohkubo, Hiroyuki Tominaga, Kenichi Tomita, Kenzo ...
    2008 Volume 51 Issue 9 Pages 849-860
    Published: 2008
    Released on J-STAGE: May 20, 2009
    DOIhttps://doi.org/10.11213/tonyobyo.51.849
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Complex genotype/phenotype relationships have been reported in congenital partial lipodystrophy. The patient was a 33-year-old female with progeroid features and hyperinsulinemia, insulin resistance associated with metabolic abnormalities including not only diabetes, hypertension, fatty liver, hirsutism, polycystic ovary syndrome, acanthosis nigricans, as well as a also short stature and a sensorineural deafness. Her body fat distribution was the characteristic pattern of “partial lipodystrohy” which showed a generalized subcutaneous fat loss, but an excessive accumulation of intraabdominal fat. Low fasting plasma leptin and adiponectin levels were observed. No Lamin A/C or PPARγ mutations were identified. Normal insulin receptor binding and an abnormality in the post IRS-1 signaling pathway were found by a primary fibroblast culture. She was tentatively diagnosed to have either the sporadic Köbberling type or a variety of congenital [familial] partial lipodystropy (referred to in publications as the “FPLD1”). We herein present our long-term experience of treating this case with pioglitazone. Both subcutaneous and visceral fat increased following this treatment in addition the leptin and adiponectin levels also increased. An increased insulin sensitivity and improvements in both glucose intolerance and liver dysfunction were also observed during the follow-up period. This case therefore demonstrated the benefits of PPARγ-agonists, pioglitazone on metabolic abnormalities in a patient with Köbberling type of FPLD without any adverse side effects. A large series of pioglitazone treatment cases should therefore be studied to elucidate the efficacy of this treatment regimen for genetically different types of FPLD.
    View full abstract
    Download PDF (1710K)
  • Repeated Episodes of Ketosis Observed in a Case of Type 2 Diabetes
    T. Katsuki, Y. Oikawa, A. Shimada, H. Itoh
    2008 Volume 51 Issue 9 Pages 861-865
    Published: 2008
    Released on J-STAGE: May 20, 2009
    DOIhttps://doi.org/10.11213/tonyobyo.51.861
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    [in Japanese]
    View full abstract
    Download PDF (317K)
  • A Case of Insulin Autoimmune Syndrome Probably Induced by Ingestion of α-Lipoic Acid Associated with Diabetic Ketoacidosis
    Mutsuo Beniko, Hitomi Kudo, Noriko Toyoshima, Akira Matsumoto, Masatom ...
    2008 Volume 51 Issue 9 Pages 867-871
    Published: 2008
    Released on J-STAGE: May 20, 2009
    DOIhttps://doi.org/10.11213/tonyobyo.51.867
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Insulin autoimmune syndrome (IAS) usually involves hypoglycemia and insulin autoantibody (IAA) without prior insulin administration. We report a unique case of IAS with diabetic ketoacidosis (DKA). A 44-year-old woman had started taking α-lipoic acid (ALA) for dietary purposes, and was admitted for DKA. Laboratory findings were compatible with DKA, whereas serum IRI concentration before insulin therapy was extremely high (5,644 μU/ml). After DKA therapy, she discontinued insulin injection. She was diagnosed with IAS because of high IAA titer (99%: bound/total) and a negative history of exposure to exogenous insulin until this episode. Strong binding of most of the secreted insulin to IAA depleted free insulin. Her HLA genotype contains DRB1*0406 and ALA is known as the novel agent causing IAS. IAA titer gradually decreased after the cessation of ALA, and hypoglycemic attack hasn't ever happened. She is probably the first case of IAS with DKA. Considering the growing use of health supplements, we should pay attention to ingestion of those such as ALA.
    View full abstract
    Download PDF (496K)
Co-medical
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top